Table 2. Identification of plasma metabolites of normotensive and prehypertensive subjects.
Identity | Formula | Exact Mass | Mass Error (mDa) | Normalized Peak Intensities | Fold Changea | P | P′ | P″ | VIP | |
[M + H]+ | (M + H) | (mDa) | Normotensive Group (n = 53) | Prehypertensive Group (n = 53) | ||||||
L-Leucine | C6H13NO2 | 132.1025 | −1.3 | 3,676,275±105,146 | 3,988,998±96,549 | 1.09 | 0.031 | 0.055 | 0.248 | 2.045 |
L-Phenylalanine | C9H11NO2 | 166.0868 | −1.4 | 2,247,548±54,466 | 2,415,093±58,200 | 1.07 | 0.038 | 0.157 | 0.404 | 1.079 |
L-Tryptophan | C11H12N2O2 | 205.0977 | −1.3 | 1,572,767±57,695 | 1,760,331±62,565 | 1.12 | 0.030 | 0.100 | 0.187 | 1.225 |
Palmitic amide | C16H33NO | 256.2640 | −2.1 | 711,550±97,369 | 703,228±82,904 | 0.99 | 0.948 | 0.853 | 0.543 | 1.156 |
Oleamide | C18H35NO | 282.2797 | −2.2 | 4,551,082±418,609 | 4,714,739±407,173 | 1.04 | 0.780 | 0.760 | 0.621 | 4.818 |
LysoPC (14:0) | C22H46NO7P | 468.3090 | −3.6 | 261,210±14,207 | 413,695±18,650 | 1.58 | <0.001 | <0.001 | <0.001 | 1.028 |
LysoPC (16:1) | C24H48NO7P | 494.3247 | −3.3 | 551,486±21,985 | 911,147±30,487 | 1.65 | <0.001 | <0.001 | <0.001 | 2.471 |
LysoPC (16:0) | C24H50NO7P | 496.3403 | −3.6 | 9,219,069±155,236 | 11,815,774±183,606 | 1.28 | <0.001 | <0.001 | <0.001 | 17.499 |
LysoPC (18:2) | C26H50NO7P | 520.3403 | −4.1 | 3,670,567±113,737 | 4,603,096±140,602 | 1.25 | <0.001 | <0.001 | <0.001 | 6.010 |
LysoPC (18:1) | C26H52NO7P | 522.3560 | −4.6 | 3,256,978±88,919 | 4,299,302±103,385 | 1.32 | <0.001 | <0.001 | <0.001 | 6.867 |
LysoPC (18:0) | C26H54NO7P | 524.3716 | −4.5 | 4,354,018±129,401 | 5,339,069±144,196 | 1.23 | <0.001 | <0.001 | 0.001 | 5.852 |
LysoPC (20:5) | C28H48NO7P | 542.3247 | −3.9 | 437,396±18,626 | 597,653±28,416 | 1.37 | <0.001 | <0.001 | 0.001 | 1.088 |
LysoPC (20:4) | C28H50NO7P | 544.3403 | −4.0 | 941,761±23,633 | 1,285,336±35,484 | 1.36 | <0.001 | <0.001 | <0.001 | 2.341 |
LysoPC (20:3) | C28H52NO7P | 546.3560 | −4.3 | 388,869±19,137 | 592,630±20,649 | 1.52 | <0.001 | <0.001 | <0.001 | 1.396 |
LysoPC (22:6) | C30H50NO7P | 568.3403 | −4.1 | 537,886±21,797 | 807,587±30,720 | 1.50 | <0.001 | <0.001 | <0.001 | 1.808 |
PC (16:0/18:2) | C42H80NO8P | 758.5700 | −5.6 | 4,847,743±352,770 | 4,938,788±384,917 | 1.02 | 0.862 | 0.713 | 0.602 | 3.297 |
PC (16:1/20:4) | C44H78NO8P | 780.5543 | −5.0 | 837,185±114,131 | 835,170±157,967 | 1.00 | 0.992 | 0.964 | 0.719 | 1.534 |
PC (18:2/18:2) | C44H80NO8P | 782.5700 | −5.1 | 1,875,687±156,964 | 2,156,458±157,026 | 1.15 | 0.209 | 0.410 | 0.528 | 2.191 |
PC (18:0/18:2) | C44H84NO8P | 786.6013 | −5.8 | 1,200,418±89,200 | 1,347,258±99,846 | 1.12 | 0.275 | 0.473 | 0.639 | 1.791 |
Lactosylceramide (d18:1/12:0) | C42H79NO13 | 806.5630 | 2.6 | 1,832,933±253,443 | 1,436,077±185,650 | 0.78 | 0.209 | 0.269 | 0.548 | 2.824 |
Means ± S.E. aCalculated by the mean intensity of each metabolite from the prehypertensive group divided by the mean intensity of each metabolite from the normotensive group. P-values derived from independent t-tests. P′-values derived from independent t-tests after adjusting for BMI, WHR, smoking, alcohol consumption, total-cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, glucose, free fatty acid, and insulin. P″-values derived from independent t-tests after adjusting for BMI, WHR, smoking, alcohol consumption, total-cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, glucose, free fatty acid, insulin, Lp-PLA2, and ox-LDL.